Rapport Therapeutics Inc. (RAPP)
$22.05
+1.64
(+8.04%)▲
Market is closed - opens 7 PM, 14 Oct 2024
Performance
- $20.31$22.14$22.05
7.89%
Downside
Day's Volatility :8.27%
Upside
0.41%
- $16.55$28.08$22.05
24.94%
Downside
52 Weeks Volatility :41.06%
Upside
21.47%
Returns
| Period | Rapport Therapeutics Inc. | Index (Russel 2000) |
|---|---|---|
3 Months | -11.8% | 0.0% |
6 Months | 6.01% | 0.0% |
1 Year | 6.01% | 0.0% |
3 Years | 6.01% | -21.1% |
Highlights
Market Capitalization | 762.3M |
Book Value | $9.21 |
Earnings Per Share (EPS) | -1.72 |
Wall Street Target Price | 35.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -61.8M |
Diluted Eps TTM | -1.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.46 |
EPS Estimate Next Year | -3.04 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 58.73%
Current $22.05
Target $35.00
Technicals Summary
Sell
Neutral
Buy
Rapport Therapeutics Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Rapport Therapeutics Inc. | 16.05% | 6.01% | 6.01% | 6.01% | 6.01% |
 Regeneron Pharmaceuticals, Inc. | -11.94% | 13.03% | 20.97% | 85.64% | 232.53% |
 Novo Nordisk A/s | -12.38% | -3.12% | 17.52% | 138.65% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 7.18% | 92.5% | 69.12% | 39.45% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -0.75% | 21.23% | 29.84% | 165.64% | 177.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Rapport Therapeutics Inc. | NA | NA | NA | -3.46 | 0.0 | 0.0 | NA | 9.21 |
Regeneron Pharmaceuticals, Inc. | 26.88 | 26.88 | 1.38 | 45.01 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.8 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Rapport Therapeutics Inc. | NA | $762.3M | 6.01% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.1B | 232.53% | 26.88 | 32.04% |
Novo Nordisk A/s | Buy | $523.9B | 361.43% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $124.3B | 177.5% | 32.84 | -4.74% |
Company Information
Organization | Rapport Therapeutics Inc. |
Employees | 0 |
CEO | Dr. Steven M. Paul M.D. |
Industry | Miscellaneous |
Discover More
Orion Energy Systems Inc
$22.05
+8.04%
Innovator Intl Developed Power Buffer Etf - June
$22.05
+8.04%
Bny Mellon Concentrated Intl
$22.05
+8.04%
Fidelity International Multifactor Etf
$22.05
+8.04%
Innovator Us Equity Accelerated Plus Etf - April
$22.05
+8.04%
Amplify Seymour Cannabis Etf
$22.05
+8.04%
Ebang International Holdings Inc
$22.05
+8.04%
Yieldmax Ai Option Income Strategy Etf
$22.05
+8.04%
First Trust Ultra Short Duration Municipal Etf
$22.05
+8.04%